Xcout Intel
D3 Bio competitors & alternatives
The 12 closest competitors and alternatives to D3 Bio among biotechnology companies — ranked by similarity to what D3 Bio actually does, not by market-cap band.
Subscribe to see D3 Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About D3 Bio
D3 Bio is a biopharmaceutical company headquartered in Shanghai, China, focused on the discovery and development of innovative oncology and immunology medicines.
D3 Bio at a glance
D3 Bio is a biotechnology company headquartered in China. Its most recent funding round, Series B, raised $108M in December 2025. Xcout tracks 3 named people at D3 Bio, including George Chen (Founder, Chairman & CEO).
D3 Bio leadership
- George ChenFounder, Chairman & CEO
- John JinCo-Founder, CFO, CBO, & Board Member
- Antoine YverIndependent Board Member
D3 Bio funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $108M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 D3 Bio competitors
Ranked by semantic similarity — how close each company is to D3 Bio by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Lyvgen Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immune-oncology therapies. Founded in 2016, the company maintains its headquarters in Shanghai, China, alongside research facilities in Suzhou.
Biotech
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
Biotech
Operating as a clinical-stage enterprise, Duality Biotherapeutics, Inc. concentrates on pioneering next-generation antibody-drug conjugate (ADC) therapies and proprietary duality immune toxin antibody conjugate (ITAC) solutions. The firm was founded by Zhu Zhong Yuan on July 3, 2019, and its main offices are situated in Shanghai, China.
Biotech
Inventisbio is a biopharmaceutical company that focuses on the discovery and development of innovative drugs for major diseases such as tumors, autoimmune diseases, and metabolic disorders. Utilizing an independent research and development platform, the company creates proprietary drug pipelines targeting oncology drivers, kinases, and autoimmune pathways to serve patients globally.
Similar biotechnology company
ImmuXell Biotechnology is a clinical-stage biopharmaceutical innovation company headquartered in Shanghai, China. Founded in 2021, the company focuses on developing novel immune cell therapies targeted at treating solid tumor cancers.
Similar biotechnology company
Allink Biotherapeutics is a clinical-stage biotechnology company founded in 2023 and based in Shanghai, China, focused on developing advanced antibody-drug conjugates (ADCs) and therapeutics.
Similar biotechnology company
ETERN Therapeutics is a biopharmaceutical company headquartered in Shanghai, China, operating with a strong academic atmosphere and focus on biotechnology.
Biotech
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Similar biotechnology company
Chimagen Biosciences is a biopharmaceutical company headquartered in Shanghai, China, founded in July 2016. The company specializes in multi-specific antibody therapeutics and built the proprietary TRIAD platform for engineering.
Similar biotechnology company
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
Biotech
Deka Biosciences, Inc. is an early-stage biotechnology holding company located in Germantown, Maryland, focused on developing and delivering life-changing medicines for cancer patients.
Similar biotechnology company
Full-Life Technologies Limited is a fully integrated global radiopharmaceutical company focused on drug development in oncology, headquartered in Shanghai, China, with additional operations in Europe.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of D3 Bio and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for D3 Bioand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →